Sex and sniffles prove good for Reckitt
Your support helps us to tell the story
As your White House correspondent, I ask the tough questions and seek the answers that matter.
Your support enables me to be in the room, pressing for transparency and accountability. Without your contributions, we wouldn't have the resources to challenge those in power.
Your donation makes it possible for us to keep doing this important work, keeping you informed every step of the way to the November election
![Head shot of Andrew Feinberg](https://static.independent.co.uk/static-assets/support-us/andrew-feinberg.png)
Andrew Feinberg
White House Correspondent
Reckitt Benckiser thanked strong demand for cold and flu remedies and for Durex condoms for its 3 per cent rise in profits last year.
The consumer goods giant, which also makes Nurofen painkillers and Dettol disinfectant, beat City expectations as pre-tax profits edged up 2 per cent to £2.4bn after exceptional costs, mainly relating to restructuring, rose to £135m.
Reckitt said "higher incidences of cold and flu" had triggered a leap in demand for its Strepsils sore throat sweets and Mucinex chesty cough medicine in Europe and North America in the fourth quarter. And Durex's new Performax Intense condoms, plus expansion in China, had given the condom brand "a particularly strong quarter".
Rakesh Kapoor, who took over as chief executive from Bart Brecht in 2011, said: "We are now setting the target of … our emerging market areas to become 50 per cent of our core business net revenue by 2015."
Mr Kapoor forecast that sales this year would rise as much as 6 per cent, boosted by acquisitions. Reckitt bought a "modest-sized" traditional Chinese medicine company and earlier this week announced a $482m (£308m) deal with the US group Bristol-Myers Squibb to sell over-the-counter drugs in Brazil and Mexico.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments